{"id":69577,"date":"2026-07-08T13:57:27","date_gmt":"2026-07-08T05:57:27","guid":{"rendered":"https:\/\/flcube.com\/?p=69577"},"modified":"2026-07-08T13:57:28","modified_gmt":"2026-07-08T05:57:28","slug":"mindrank-secures-52-million-series-b-to-advance-ai-drug-discovery-platform-and-phase-iii-glp-1ra-candidate-mdr-001","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69577","title":{"rendered":"MindRank Secures $52 Million Series B to Advance AI Drug Discovery Platform and Phase III GLP-1RA Candidate MDR-001"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>MindRank<\/strong>, a clinical-stage <strong>AI-native drug discovery company<\/strong>, announced the completion of a <strong>$52 million Series B financing round<\/strong> conducted in stages, with participation from multiple <strong>renowned investment institutions and industrial funds<\/strong>. The capital will accelerate development of its proprietary <strong>full-chain AI drug discovery engine MAP (Molecule Arts Platform)<\/strong> and advance its <strong>oral GLP-1RA small-molecule candidate MDR-001<\/strong> through <strong>Phase III clinical trials<\/strong> toward commercialization.<\/p>\n\n\n\n<h2 id=\"h-financing-details-amp-strategic-allocation\" class=\"wp-block-heading\">Financing Details &amp; Strategic Allocation<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>MindRank (private)<\/td><\/tr><tr><td><strong>Round<\/strong><\/td><td>Series B<\/td><\/tr><tr><td><strong>Amount<\/strong><\/td><td>USD 52 million (aggregate, staged closing)<\/td><\/tr><tr><td><strong>Investors<\/strong><\/td><td>Multiple institutional and industrial funds<\/td><\/tr><tr><td><strong>Primary Use of Proceeds<\/strong><\/td><td>1. MAP platform technological iteration<br>2. MDR-001 Phase III clinical development<br>3. Innovative pipeline expansion<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>8 July 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-technology-platform-amp-core-innovation\" class=\"wp-block-heading\">Technology Platform &amp; Core Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>MAP (Molecule Arts Platform)<\/strong>: An <strong>all-in-one AI platform<\/strong> that deeply integrates <strong>biology, structural biology, chemistry, and medicine<\/strong> through proprietary machine learning, reinforcement learning, and first-principles computational approaches.<\/li>\n\n\n\n<li><strong>Multi-Agent Collaboration Framework<\/strong>: Industry-leading system enabling autonomous AI agents to collaborate across drug discovery workflows, from target identification to lead optimization.<\/li>\n\n\n\n<li><strong>Clinical Data-in-the-Loop System<\/strong>: Proprietary feedback mechanism that continuously incorporates clinical trial data to refine predictive models and improve compound selection accuracy.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">MindRank&#8217;s <strong>AI-native approach<\/strong> represents a paradigm shift from traditional drug discovery, leveraging computational power to reduce development timelines and increase success rates across therapeutic areas.<\/p>\n\n\n\n<h2 id=\"h-lead-clinical-asset-mdr-001\" class=\"wp-block-heading\">Lead Clinical Asset: MDR-001<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Compound<\/strong>: <strong>Oral GLP-1RA small-molecule<\/strong> innovative drug<\/li>\n\n\n\n<li><strong>Development Stage<\/strong>: <strong>Phase III clinical studies<\/strong> (entered 2025)<\/li>\n\n\n\n<li><strong>Therapeutic Area<\/strong>: Metabolic disorders (obesity, type 2 diabetes)<\/li>\n\n\n\n<li><strong>Differentiation<\/strong>: Oral bioavailability in a class traditionally dominated by injectable peptide therapeutics<\/li>\n\n\n\n<li><strong>Commercial Potential<\/strong>: Addresses multi-billion dollar market with improved patient compliance and accessibility<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The GLP-1 receptor agonist market has seen explosive growth following the success of semaglutide and tirzepatide, creating significant opportunity for differentiated oral alternatives.<\/p>\n\n\n\n<h2 id=\"h-pipeline-strategy-amp-market-positioning\" class=\"wp-block-heading\">Pipeline Strategy &amp; Market Positioning<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>AI-Driven Portfolio Expansion<\/strong>: Beyond MDR-001, MindRank is advancing a <strong>differentiated innovative drug pipeline<\/strong> across multiple therapeutic areas, leveraging its platform&#8217;s ability to rapidly generate and optimize novel chemical entities.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Competitive Advantage<\/strong>: As one of the few <strong>clinical-stage AI-native companies<\/strong>, MindRank bridges the gap between computational innovation and real-world clinical validation, providing investors with both technological upside and near-term clinical catalysts.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Industrial Partnerships<\/strong>: The participation of <strong>industrial funds<\/strong> in the Series B suggests strategic interest from pharmaceutical partners seeking access to MindRank&#8217;s AI capabilities and pipeline assets.<\/p>\n\n\n\n<h2 id=\"h-financial-amp-development-outlook\" class=\"wp-block-heading\">Financial &amp; Development Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Burn Rate Management<\/strong>: Staged financing structure provides capital efficiency while maintaining optionality for future strategic partnerships or additional funding rounds.<\/li>\n\n\n\n<li><strong>Timeline Acceleration<\/strong>: Additional resources expected to compress Phase III timelines for MDR-001, potentially enabling regulatory submissions as early as 2027.<\/li>\n\n\n\n<li><strong>Platform Monetization<\/strong>: Beyond internal pipeline development, MindRank may explore platform licensing opportunities with larger pharmaceutical companies seeking AI-enabled drug discovery capabilities.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking information regarding financing, clinical development, and business strategy. Actual results may differ due to clinical trial outcomes, regulatory decisions, competitive dynamics, and market conditions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>MindRank, a clinical-stage AI-native drug discovery company, announced the completion of a $52 million Series&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[99,20,765],"class_list":["post-69577","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-ai","tag-finance","tag-mindrank"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>MindRank Secures $52 Million Series B to Advance AI Drug Discovery Platform and Phase III GLP-1RA Candidate MDR-001 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"MindRank, a clinical-stage AI-native drug discovery company, announced the completion of a $52 million Series B financing round conducted in stages, with participation from multiple renowned investment institutions and industrial funds. The capital will accelerate development of its proprietary full-chain AI drug discovery engine MAP (Molecule Arts Platform) and advance its oral GLP-1RA small-molecule candidate MDR-001 through Phase III clinical trials toward commercialization.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69577\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MindRank Secures $52 Million Series B to Advance AI Drug Discovery Platform and Phase III GLP-1RA Candidate MDR-001\" \/>\n<meta property=\"og:description\" content=\"MindRank, a clinical-stage AI-native drug discovery company, announced the completion of a $52 million Series B financing round conducted in stages, with participation from multiple renowned investment institutions and industrial funds. The capital will accelerate development of its proprietary full-chain AI drug discovery engine MAP (Molecule Arts Platform) and advance its oral GLP-1RA small-molecule candidate MDR-001 through Phase III clinical trials toward commercialization.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69577\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-08T05:57:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-08T05:57:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69577#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69577\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"MindRank Secures $52 Million Series B to Advance AI Drug Discovery Platform and Phase III GLP-1RA Candidate MDR-001\",\"datePublished\":\"2026-07-08T05:57:27+00:00\",\"dateModified\":\"2026-07-08T05:57:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69577\"},\"wordCount\":489,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"AI\",\"Finance\",\"MindRank\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69577#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69577\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69577\",\"name\":\"MindRank Secures $52 Million Series B to Advance AI Drug Discovery Platform and Phase III GLP-1RA Candidate MDR-001 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-08T05:57:27+00:00\",\"dateModified\":\"2026-07-08T05:57:28+00:00\",\"description\":\"MindRank, a clinical-stage AI-native drug discovery company, announced the completion of a $52 million Series B financing round conducted in stages, with participation from multiple renowned investment institutions and industrial funds. The capital will accelerate development of its proprietary full-chain AI drug discovery engine MAP (Molecule Arts Platform) and advance its oral GLP-1RA small-molecule candidate MDR-001 through Phase III clinical trials toward commercialization.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69577#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69577\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69577#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MindRank Secures $52 Million Series B to Advance AI Drug Discovery Platform and Phase III GLP-1RA Candidate MDR-001\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"MindRank Secures $52 Million Series B to Advance AI Drug Discovery Platform and Phase III GLP-1RA Candidate MDR-001 - Insight, China&#039;s Pharmaceutical Industry","description":"MindRank, a clinical-stage AI-native drug discovery company, announced the completion of a $52 million Series B financing round conducted in stages, with participation from multiple renowned investment institutions and industrial funds. The capital will accelerate development of its proprietary full-chain AI drug discovery engine MAP (Molecule Arts Platform) and advance its oral GLP-1RA small-molecule candidate MDR-001 through Phase III clinical trials toward commercialization.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69577","og_locale":"en_US","og_type":"article","og_title":"MindRank Secures $52 Million Series B to Advance AI Drug Discovery Platform and Phase III GLP-1RA Candidate MDR-001","og_description":"MindRank, a clinical-stage AI-native drug discovery company, announced the completion of a $52 million Series B financing round conducted in stages, with participation from multiple renowned investment institutions and industrial funds. The capital will accelerate development of its proprietary full-chain AI drug discovery engine MAP (Molecule Arts Platform) and advance its oral GLP-1RA small-molecule candidate MDR-001 through Phase III clinical trials toward commercialization.","og_url":"https:\/\/flcube.com\/?p=69577","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-08T05:57:27+00:00","article_modified_time":"2026-07-08T05:57:28+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69577#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69577"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"MindRank Secures $52 Million Series B to Advance AI Drug Discovery Platform and Phase III GLP-1RA Candidate MDR-001","datePublished":"2026-07-08T05:57:27+00:00","dateModified":"2026-07-08T05:57:28+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69577"},"wordCount":489,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["AI","Finance","MindRank"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69577#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69577","url":"https:\/\/flcube.com\/?p=69577","name":"MindRank Secures $52 Million Series B to Advance AI Drug Discovery Platform and Phase III GLP-1RA Candidate MDR-001 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-08T05:57:27+00:00","dateModified":"2026-07-08T05:57:28+00:00","description":"MindRank, a clinical-stage AI-native drug discovery company, announced the completion of a $52 million Series B financing round conducted in stages, with participation from multiple renowned investment institutions and industrial funds. The capital will accelerate development of its proprietary full-chain AI drug discovery engine MAP (Molecule Arts Platform) and advance its oral GLP-1RA small-molecule candidate MDR-001 through Phase III clinical trials toward commercialization.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69577#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69577"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69577#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"MindRank Secures $52 Million Series B to Advance AI Drug Discovery Platform and Phase III GLP-1RA Candidate MDR-001"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69577","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69577"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69577\/revisions"}],"predecessor-version":[{"id":69578,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69577\/revisions\/69578"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69577"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69577"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69577"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}